An FPP synthase inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Alendronate (sodium hydrate)

Item No. 13642

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
P,P'-(4-amino-1-hydroxybutylidene)bis-phosphonic acid, monosodium salt trihydrate (1:1:3)
CAS Number
121268-17-5
Synonyms
  • Adronat
  • Fosamax
  • G-704650
  • MK-217
Molecular Formula
C4H12NO7P2 • H6NaO3
Formula Weight
325.1
Purity
≥95%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 0.25 mg/ml
SMILES
NCCCC(P(O)([O-])=O)(O)P(O)(O)=O.[Na+]
InChi Code
InChI=1S/C4H13NO7P2.Na/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);/q;+1/p-1
InChi Key
CAKRAHQRJGUPIG-UHFFFAOYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 mg

    $31

    Add

    250 mg

    $66

    Add

    500 mg

    $107

    Add

    1 g

    $129

    Add
    Product Description

    Alendronate is an amino bisphosphonate that inhibits farnesyl pyrophosphate (FPP) synthase (IC50 = 50 nM for the recombinant human enzyme).1 It inhibits bone resorption in a pit formation assay using isolated rat osteoclasts (IC50 = 2 nM).2 Alendronate (3 and 10 µM) reduces angiotensin II-induced collagen I synthesis in isolated rat cardiac fibroblasts.3 It prevents femoral bone mineral density loss in ovariectomized rats when administered at a dose of 5 mg/kg.4 Formulations containing alendronate have been used in the treatment of osteoporosis and Paget's disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Dunford, J.E., Thompson, K., Coxon, F.P., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296(2), 235-242 (2001).

    2. Sahni, M., Guenther, H.L., Fleisch, H., et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 91(5), 2004-2011 (1993).

    3. Ye, Y., Lv, X., Wang, M.-h., et al. Alendronate prevents angiotensin II-induced collagen I production through geranylgeranylation-dependent RhoA/Rho kinase activation in cardiac fibroblasts. J. Pharmacol. Sci. 129(4), 205-209 (2015).

    4. Azuma, Y., Oue, Y., Kanatani, H., et al. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: Comparison with pamidronate and etidronate in growing rats. J. Pharmacol. Exp. Ther. 286(1), 128-135 (1998).